BioPharma Continues Expansion Plan with Acquisition of HauserContract Research Organization

BioPharma Continues Expansion Plan with Acquisition of HauserContract Research Organization

HILLSIDE, N.J.IntegratedBioPharma (IB) (AMEX:INB) entered into an agreement with Hauser Inc. to acquireHauser Contract Research Organization (Hauser CRO), a business involved in theextraction, isolation, purification and synthetic modification of naturalproducts from plant, marine and microbial sources. The transaction is slated toclose in September, pending court approval.

Hauser CRO is expected to provide revenues, an establishedcustomer base and expanded analytical capabilities to further IBs expansiongoals. Together with Paxis Pharmaceuticals Inc., another wholly ownedsubsidiary, Hauser CRO will also furnish IB with the complete capability tocreate Active Pharmaceutical Ingredients (API) for itself and customers. Paxis,in conjunction with Hauser CRO, now has a substantial platform to leverage itsmodern and recently updated manufacturing plant into the development andmanufacture of a variety of API products for itself and customers. In addition,Paxis will be able to provide complete development of API from concept toproduction.

The CRO acquisition enhances our position as a manufacturerof Active Pharmaceutical Ingredients, said INB Chief Executive Officer E.

Gerald Kay. This should provide for additionalopportunities for both taxane-based novel drug candidates and othernon-taxane-based naturally derived and semi-synthetic pharmaceuticals.